0280/2021 - CARACTERIZACIÓN DE LAS SOLICITUDES DE IMPORTACIÓN DE MEDICAMENTOS VITALES NO DISPONIBLES AÑOS 2016 Y 2017 EN COLOMBIA. CARACTERIZACIÓN DE LAS SOLICITUDES DE IMPORTACIÓN DE MEDICAMENTOS VITALES NO DISPONIBLES AÑOS 2016 Y 2017 EN COLOMBIA.
En este estudio observacional descriptivo de corte transversal se incluyeron todas analizaron las solicitudes de importación de Medicamentos vitales no disponibles (MVND) presentadas en elal INVIMA durante el periodo 2016-2017, así como y los registros de solicitudes de recobros presentados en la ADRES, durante por MVND, en el mismo periodo. Se analizaron 2016-2017. De las 2321 solicitudes de importación, de las cualesMVND, el 76% de las solicitudes fueron autorizadas. Se identificaron en total 88 solicitantes, 73 subgrupos terapéuticos acorde al código ATC y 195 principios activos solicitados., así como 368 diagnósticos. El 66,6% de los pacientes registrados en las solicitudes de importación se encuentran vinculados al régimen contributivo, en menor proporción al régimen subsidiado y al régimen especial o excepción. Se identificaron en total 368 diagnósticos en las solicitudes para paciente especifico, en caso de urgencia clínica y varios pacientes.excepcional. En solicitudes de recobros asociados a MVND por vía judicial, se observó que, el monto solicitado por recobro fue de $ 25.315.191.295. Los medicamentos mayormente solicitados como MVND son el reflejo de problemáticas de salud pública que merecen ser atendidas y que, en algunas ocasiones, recurren a la vía judicial desfigurando los criterios médicos y desequilibrando el presupuesto otorgado al gasto en saludUSD 8.577.583, equivalentes a 38483 UPCs. Los resultados mostraron que la implementación del decreto 481 de 2004 ha sido útil para garantizar el acceso a medicamentos para enfermedades raras, aunque no es ajena a la inequidad estructural de acceso a servicios de salud y medicamentos del SGSSS y que generan impacto, no solo en la salud pública, si no en el presupuesto asignado, bien sea por el alto costo que implica su importación o por la falta de regulación de estos dentro del mercado nacional.
Palavras-chave:
Palabras claves: Acceso a Medicamentos Esenciales y Tecnologías Sanitarias, Enfermedades Raras, Medicamentos Huérfanos, Costos de los Medicamentos, Colombia.
Abstract:
This cross-sectional descriptive observationalIn this study includes all, the import requests for vital medicines not available (MVND) presented atsubmitted to INVIMA during the 2016-2017 period, as well as and the records of recovery requests presented at submitted to the ADRES, during by MVND, in the same period. 2321 import applications 2016-2017, were analyzed, of which. Of the 2321 MVND import requests, 76% were authorized. A total of 88 applicants were identified, 73 therapeutic subgroups according to the ATC code and 195 active ingredients applied for. 66.6principles, as well as 368 diagnoses were identified. 66% of the patients registered in the import applications are linked to the contributory regime and in, to a lesser extent, to the subsidized regime and to the special or exception regime. A total of 368 diagnoses were identified in the requests for specific patients in the category of clinical emergency.exceptional regime. In judicial recovery requests associated with MVND, it was observed that the amount requested for recovery was $ 25,315,191,295.USD 8,577,583, equivalent to 38,483 UPCs. The drugs most requested as MVND are the reflection of public health problemsresults showed that deserve to be addressedthe implementation of Decree 481 of 2004 has been useful to guarantee access to medicines for rare diseases, although it is not alien to the structural inequity of access to health services and medicines of the SGSSS and that, on some occasions, resort to judicial means, distorting medical criteria and unbalancing they generate impact, not only in public health, if not within the budget allocated to health spendingbudget, either because of the high cost of importing them or because of the lack of regulation of these within the national market.
Keywords:
Access to Essential Medicines and Health Technologies, Rare Diseases, Orphan Drugs, Drug Costs, Colombia.
CARACTERIZACIÓN DE LAS SOLICITUDES DE IMPORTACIÓN DE MEDICAMENTOS VITALES NO DISPONIBLES AÑOS 2016 Y 2017 EN COLOMBIA.
Resumo (abstract):
This cross-sectional descriptive observationalIn this study includes all, the import requests for vital medicines not available (MVND) presented atsubmitted to INVIMA during the 2016-2017 period, as well as and the records of recovery requests presented at submitted to the ADRES, during by MVND, in the same period. 2321 import applications 2016-2017, were analyzed, of which. Of the 2321 MVND import requests, 76% were authorized. A total of 88 applicants were identified, 73 therapeutic subgroups according to the ATC code and 195 active ingredients applied for. 66.6principles, as well as 368 diagnoses were identified. 66% of the patients registered in the import applications are linked to the contributory regime and in, to a lesser extent, to the subsidized regime and to the special or exception regime. A total of 368 diagnoses were identified in the requests for specific patients in the category of clinical emergency.exceptional regime. In judicial recovery requests associated with MVND, it was observed that the amount requested for recovery was $ 25,315,191,295.USD 8,577,583, equivalent to 38,483 UPCs. The drugs most requested as MVND are the reflection of public health problemsresults showed that deserve to be addressedthe implementation of Decree 481 of 2004 has been useful to guarantee access to medicines for rare diseases, although it is not alien to the structural inequity of access to health services and medicines of the SGSSS and that, on some occasions, resort to judicial means, distorting medical criteria and unbalancing they generate impact, not only in public health, if not within the budget allocated to health spendingbudget, either because of the high cost of importing them or because of the lack of regulation of these within the national market.
Palavras-chave (keywords):
Access to Essential Medicines and Health Technologies, Rare Diseases, Orphan Drugs, Drug Costs, Colombia.
Olivares, L. A., Vargas-Peláez, C. M., Lopez, J. J., Rossi, F., Chacón-Garzón, M.F.. CARACTERIZACIÓN DE LAS SOLICITUDES DE IMPORTACIÓN DE MEDICAMENTOS VITALES NO DISPONIBLES AÑOS 2016 Y 2017 EN COLOMBIA.. Cien Saude Colet [periódico na internet] (2021/ago). [Citado em 22/12/2024].
Está disponível em: http://cienciaesaudecoletiva.com.br/artigos/caracterizacion-de-las-solicitudes-de-importacion-de-medicamentos-vitales-no-disponibles-anos-2016-y-2017-en-colombia/18179?id=18179&id=18179
